Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
Krystal Biotech pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Krystal Biotech's pe ratio was 38.7× on Nov 11, 2026, against 32.7× a year earlier. Over the last 3 years it ranged from 30.0× to 459.6×, with a median of 45.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 38.7× | +1.7 |
| 2025 | Dec 31, 2025 | 37.0× | −49.1 |
| 2024 | Dec 31, 2024 | 86.0× | – |
See a number that looks wrong?